ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,948.71
0.53%
Dow Jones
43,870.35
1.06%
US Dollar vs MXN
20.39965
-0.11%
Brent Oil
74.30
0.50%
Bitcoin
99,468.32
0.97%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Belite Bio Inc (BLTE)

  7. Belite Bio Inc (BLTE) Noticias

Belite Bio Inc

Belite Bio Inc (BLTE)

NASDAQ
82.45
-0.08
(-0.10%)
Cerrado 22 Noviembre 3:00PM
Delayed by 15 minutes
82.46
0.01
(0.01%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

BLTE Noticias

Solo noticias oficiales

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
20 Noviembre 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
19 Noviembre 2024
BLTE (-0.10%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
04 Noviembre 2024
BLTE (-0.10%)

Form 144/A - Report of proposed sale of securities: [Amend]
Edgar (US Regulatory)
08 Octubre 2024
BLTE (-0.10%)

Form 144/A - Report of proposed sale of securities: [Amend]
Edgar (US Regulatory)
08 Octubre 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
03 Octubre 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
03 Octubre 2024
BLTE (-0.10%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
01 Octubre 2024
BLTE (-0.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
20 Septiembre 2024
BLTE (-0.10%)

BLTE Discussion

Ver más
Monksdream Monksdream 2 meses hace
BLTE will it break out
👍️0
conix conix 2 años hace
Short Interest for BLTE--Up 30%

https://www.etfdailynews.com/2022/09/17/short-interest-in-belite-bio-inc-nasdaqblte-expands-by-30-1/
👍️0
conix conix 2 años hace
BLTE News

https://seekingalpha.com/news/3875434-blte-stock-gains-as-pivotal-trial-for-lead-asset-starts-in-us
👍️0
conix conix 2 años hace
'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst

Vandana Singh

Mon, August 1, 2022

HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ: BLTE) with a Buy rating and price target of $58 per ADS.

Belite Bio is focused on developing a novel once-daily oral drug for the treatment of Stargardt disease (STGD1)—a rare inherited juvenile-onset form of macular degeneration.

The lead drug candidate is LBS-008 (or Tinlarebant).

HC Wainwright says that as LBS-008 is administered orally once a day, it could be adopted rapidly by ophthalmologists and patients once the drug obtains regulatory approval, as the intravitreal injection procedure was found unpleasant.

"We believe LBS-008 has the potential to be developed as the first and best-in-class oral drug for the treatment of STGD1," the analyst writes.

The analyst expects the Phase 2 portion to report 1-year data in 2H22.

Meanwhile, the company has initiated a Phase 3 trial of LBS-008 in adolescent STGD1 in 1H22, slated to enroll approximately 60 patients. Enrollment for Phase 3 trial to complete in mid-2023.
👍️0
conix conix 3 años hace
Belite Bio stock soars 65% in wake of strong IPO performance

May 03, 2022 12:30 PM ETBLTEBy: Val Kennedy, SA News Editor

IPO Initial Public Offering

Mikko Lemola/iStock via Getty Images

Belite Bio (BLTE) stock soared 65% on Tuesday on the heels of a strong performance last Friday following its $36M initial public offering.

Shares of the ophthalmology drug developer opened at $10.60, recently changing hands at $14.70, up 65%, at approximately $12.05 p.m. ET.

BLTE held its IPO on April 29, offering 6 million American Depositary Shares at $6 per ADS. Underwriters were granted an option to buy up to 900k additional shares ADSs at the public price. The company’s principal stockholder, Taiwan’s Lin BioScience, agreed to buy around $15M of the offering.

The stock rocketed following the IPO on Friday, reaching a session high of $17.50 before closing at $10.59, up 77% over its offering price. The stock slid 16% on Monday.

BLTE has been focused on developing treatments for eye and metabolic diseases. The company plans to use proceeds from the IPO in part to fund Phase 3 clinical testing for its drug candidate LBS-008 for Stargardt disease and further development of the product for the treatment of dry age-related macular degeneration.
👍️0
conix conix 3 años hace
Great news

https://www.morningstar.com/news/dow-jones/202205038965/belite-bio-shares-jump-47-after-fast-track-designation-for-lbs-008-treatment-for-stargardt-disease
👍️0

Su Consulta Reciente

NASDAQ
BLTE
Belite Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados